Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Astrocyte transduction is required for rescue of behavioral phenotypes in the YAC128 mouse model with AAV-RNAi mediated HTT lowering therapeutics.

Stanek LM, Bu J, Shihabuddin LS.

Neurobiol Dis. 2019 Apr 28;129:29-37. doi: 10.1016/j.nbd.2019.04.015. [Epub ahead of print]

PMID:
31042572
2.

Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.

Cho IK, Yang B, Forest C, Qian L, Chan AWS.

PLoS One. 2019 Mar 21;14(3):e0214156. doi: 10.1371/journal.pone.0214156. eCollection 2019.

3.

Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.

Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I.

Neurobiol Dis. 2008 Jul;31(1):80-8. doi: 10.1016/j.nbd.2008.03.010. Epub 2008 Apr 16.

4.

Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.

Stanek LM, Sardi SP, Mastis B, Richards AR, Treleaven CM, Taksir T, Misra K, Cheng SH, Shihabuddin LS.

Hum Gene Ther. 2014 May;25(5):461-74. doi: 10.1089/hum.2013.200. Epub 2014 Mar 21.

5.

AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease.

Miniarikova J, Zimmer V, Martier R, Brouwers CC, Pythoud C, Richetin K, Rey M, Lubelski J, Evers MM, van Deventer SJ, Petry H, Déglon N, Konstantinova P.

Gene Ther. 2017 Oct;24(10):630-639. doi: 10.1038/gt.2017.71. Epub 2017 Aug 3.

6.
7.

Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.

Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS.

J Huntingtons Dis. 2013;2(2):217-28. doi: 10.3233/JHD-130057.

PMID:
25063516
8.

AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease.

Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D.

Mol Ther. 2008 May;16(5):947-56. doi: 10.1038/mt.2008.50. Epub 2008 Mar 25.

9.

Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Miniarikova J, Evers MM, Konstantinova P.

Mol Ther. 2018 Apr 4;26(4):947-962. doi: 10.1016/j.ymthe.2018.02.002. Epub 2018 Feb 8. Review.

10.

Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease.

Meunier C, Merienne N, Jollé C, Déglon N, Pellerin L.

Glia. 2016 Nov;64(11):1841-56. doi: 10.1002/glia.23022. Epub 2016 Jul 21.

11.

N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.

Liu X, Wang CE, Hong Y, Zhao T, Wang G, Gaertig MA, Sun M, Li S, Li XJ.

PLoS Genet. 2016 May 20;12(5):e1006083. doi: 10.1371/journal.pgen.1006083. eCollection 2016 May.

12.

Artificial miRNAs Reduce Human Mutant Huntingtin Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease.

Pfister EL, DiNardo N, Mondo E, Borel F, Conroy F, Fraser C, Gernoux G, Han X, Hu D, Johnson E, Kennington L, Liu P, Reid SJ, Sapp E, Vodicka P, Kuchel T, Morton AJ, Howland D, Moser R, Sena-Esteves M, Gao G, Mueller C, DiFiglia M, Aronin N.

Hum Gene Ther. 2018 Jun;29(6):663-673. doi: 10.1089/hum.2017.199. Epub 2018 Feb 23.

PMID:
29207890
13.

Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.

Pitzer M, Lueras J, Warden A, Weber S, McBride J.

Brain Res. 2015 May 22;1608:177-90. doi: 10.1016/j.brainres.2015.02.027. Epub 2015 Feb 28.

14.

Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice.

Wong BKY, Ehrnhoefer DE, Graham RK, Martin DDO, Ladha S, Uribe V, Stanek LM, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi MA, Shihabuddin LS, Hayden MR.

Neurobiol Dis. 2015 Apr;76:24-36. doi: 10.1016/j.nbd.2014.12.030. Epub 2015 Jan 9.

PMID:
25583186
15.

A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.

Hsiao HY, Chen YC, Chen HM, Tu PH, Chern Y.

Hum Mol Genet. 2013 May 1;22(9):1826-42. doi: 10.1093/hmg/ddt036. Epub 2013 Jan 30.

PMID:
23372043
17.

Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.

Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH, Dickson DW, Chern Y.

J Neurosci. 2008 Mar 26;28(13):3277-90. doi: 10.1523/JNEUROSCI.0116-08.2008.

18.

AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models.

Spronck EA, Brouwers CC, Vallès A, de Haan M, Petry H, van Deventer SJ, Konstantinova P, Evers MM.

Mol Ther Methods Clin Dev. 2019 Mar 16;13:334-343. doi: 10.1016/j.omtm.2019.03.002. eCollection 2019 Jun 14.

19.

Examination of mesenchymal stem cell-mediated RNAi transfer to Huntington's disease affected neuronal cells for reduction of huntingtin.

Olson SD, Kambal A, Pollock K, Mitchell GM, Stewart H, Kalomoiris S, Cary W, Nacey C, Pepper K, Nolta JA.

Mol Cell Neurosci. 2012 Mar;49(3):271-81. doi: 10.1016/j.mcn.2011.12.001. Epub 2011 Dec 8.

Supplemental Content

Support Center